A mycobacterium for use in cancer therapy
AssigneeImmodulon Therapeutics Limited
InventorsJAKOB KAMPINGA, THOMAS KLEEN
Life of this patent
Estimating the term…
Abstract
This invention provides an immunomodulator for use in the treatment, reduction, inhibition or control of cancer subject, wherein the subject is clinically classified as having a performance status of 1-, 2, 3 or 4 according to the ECOG Scale, or classified as not being of an age and/or not being sufficiently fit to tolerate two or more chemotherapy regimens. The invention also describes the use of one or more additional anticancer treatments or agents as well as protocols and dosage regimens for use.
Claims20
1-55. (canceled)
A method of treating, reducing, inhibiting or controlling cancer in a subject, wherein said subject is a human patient and wherein said method comprises simultaneously, separately or sequentially administering to the subject (i) one or more therapeutic agents and/or cancer treatments and (ii) a non-pathogenic non-viable Mycobacterium, wherein said method results in enhanced therapeutic efficacy relative to administration of one or more therapeutic agents and/or cancer treatments alone, and wherein the human patient is clinically classified as having a performance status of 1-, 2, 3 or 4 according to the Eastern Cooperative Oncology Group (ECOG) Scale.
Dependencies are inferred from the claim text.